Armata Pharmaceuticals Q4 EPS Reduced by HC Wainwright

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) - Research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Armata Pharmaceuticals in a report released on Monday, May 19th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.86) per share for the quarter, down from their previous forecast of ($0.67). HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Armata Pharmaceuticals' current full-year earnings is ($0.95) per share.

Armata Pharmaceuticals Stock Performance

Shares of ARMP stock traded up $0.02 on Wednesday, reaching $1.89. The stock had a trading volume of 84,087 shares, compared to its average volume of 68,864. The stock's 50 day simple moving average is $1.45. Armata Pharmaceuticals has a 1 year low of $0.90 and a 1 year high of $3.42. The firm has a market cap of $68.38 million, a PE ratio of -1.15 and a beta of 0.87.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.